Surface Oncology to Present at the UBS Virtual Global Healthcare Conference
13 mai 2020 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
12 mai 2020 06h20 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
23 avr. 2020 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
17 mars 2020 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019
10 mars 2020 06h20 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present at the 40th Annual Cowen Healthcare Conference
25 févr. 2020 16h05 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
27 janv. 2020 16h05 HE
|
Surface Oncology, Inc.
Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring Initial clinical updates for SRF617 and SRF388 expected by the end of 2020 Extends current...
Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference
26 nov. 2019 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures
25 nov. 2019 08h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
18 nov. 2019 06h30 HE
|
Surface Oncology, Inc.
Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors Shares preclinical data for new, CD112R targeted antibody candidate, SRF813, and its...